SEATTLE, Jan. 28, 2015 /PRNewswire/ -- Omeros
Corporation (NASDAQ: OMER) today announced its intention to offer,
subject to market and other conditions, shares of its common
stock and pre-funded warrants to purchase shares of its common
stock in a registered underwritten public offering. The pre-funded
warrants shall be offered at the same price per share as the common
stock, less the $0.01 per share
exercise price of each pre-funded warrant. Omeros also expects to
grant the underwriters a 30-day option to purchase up to an
additional 15 percent of the shares of common stock offered in the
public offering solely to cover overallotments, if any.
Omeros intends to use the net proceeds of the offering for
general corporate purposes, including expenses related to the
commercialization of Omidria™, research and development
expenses, such as funding clinical trials, pre-clinical studies,
manufacturing development and costs associated with otherwise
advancing the company's drug candidates toward New Drug Application
submissions. Omeros may also use the net proceeds for working
capital, the repayment of debt obligations, acquisitions or
investments in businesses, products or technologies that are
complementary to its own, and other capital expenditures.
Cowen and Company, LLC is acting as the sole book-running
manager for the offering.
Omeros intends to offer and sell these securities pursuant to
its existing automatic shelf registration statement (File No.
333-201581), which was filed with the Securities and Exchange
Commission on January 16, 2015 and
was automatically effective. A preliminary prospectus supplement
related to the offering will be filed with the Securities and
Exchange Commission and will form a part of the effective
registration statement. Copies of the preliminary prospectus
supplement and accompanying prospectus relating to the offering may
be obtained from Cowen and Company, LLC (c/o Broadridge Financial
Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus
Department, Phone: 631-274-2806, Fax: 631-254-7140). An electronic
copy of the preliminary prospectus supplement and accompanying
prospectus relating to the offering will be available on the
website of the Securities and Exchange Commission at
www.sec.gov.
This press release does not constitute an offer to sell or
the solicitation of an offer to buy any securities of Omeros, and
shall not constitute an offer, solicitation or sale of any security
in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction. The
offering of Omeros common stock will be made only by means of the
prospectus and related prospectus supplement meeting the
requirements of Section 10 of the Securities Act of 1933.
About Omeros Corporation
Omeros is a biopharmaceutical
company committed to discovering, developing and commercializing
small-molecule and protein therapeutics for large-market as well as
orphan indications targeting inflammation, coagulopathies and
disorders of the central nervous system.
Forward-looking Statements
This press release contains
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, which are subject to the "safe harbor"
created by those sections for such statements. All
statements other than statements of historical facts are
forward-looking statements. Terms such as "anticipate," "believe,"
"could," "estimate," "expect," "goal," "intend," "may," "plan,"
"potential," "predict," "project," "should," "will," "would," and
similar expressions and variations thereof are intended to identify
forward-looking statements, but these terms are not the exclusive
means of identifying such statements. Forward-looking
statements are based on management's beliefs and assumptions and on
information available to management only as of the date of this
press release. Omeros' actual results could differ materially from
those anticipated in these forward-looking statements for many
reasons, including, without limitation, risks associated with
Omeros' ability to begin U.S. commercial sales of
Omidria™ (OMS302) in early 2015, Omeros' ability to
obtain regulatory approval for its Marketing Authorization
Application in the EU for the commercialization of Omidria, Omeros'
unproven preclinical and clinical development activities,
regulatory oversight, product commercialization, intellectual
property claims, competitive developments, litigation, and the
risks, uncertainties and other factors described under the heading
"Risk Factors" in the company's Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on November 10, 2014. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and the company
assumes no obligation to update these forward-looking statements,
even if new information becomes available in the future.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/omeros-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-300027327.html
SOURCE Omeros Corporation